Abstract
The realisation that new chemical entities under development as drug candidates fail in three of four cases in clinical trials, together with increased costs and increased demands of reducing preclinical animal experiments, have promoted concepts for improvement of early screening procedures in humans. Positron emission tomography (PET) is a non-invasive imaging technology, which makes it possible to determine drug distribution and concentration in vivo in man with the drug labelled with a positron-emitting radionuclide that does not change the biochemical properties. Recently, developments in the field of rapid synthesis of organic compounds labelled with positron-emitting radionuclides have allowed a substantial number of new drug candidates to be labelled and potentially used as probes in PET studies. Together, these factors led to the logical conclusion that early PET studies, performed with very low drug doses—PET-microdosing—could be included in the drug development process as one means for selection or rejection of compounds based on performance in vivo in man. Another important option of PET, to evaluate drug interaction with a target, utilising a PET tracer specific for this target, necessitates a more rapid development of such PET methodology and validations in humans. Since only very low amounts of drugs are used in PET-microdosing studies, the safety requirements should be reduced relative to the safety requirements needed for therapeutic doses. In the following, a methodological scrutinising of the concept is presented. A complete pre-clinical package including limited toxicity assessment is proposed as a base for the regulatory framework of the PET-microdosing concept.
Similar content being viewed by others
References
DiMasi JA (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharm Ther 69:297–307
Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci 10:iv–xiv
Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P (1997) An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 33:142–152
Grahnen A, Karlsson MO (2001) Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 40:317–325
Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69:387–399
Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharm Ther 61:275–291
Barker J, Garner RC (1999) Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom13:285–293
Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, Cussans N, Jezequel S, Leong D (2000) A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197–209
Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development—a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205–213
Langstrom B, Kihlberg T, Bergstrom M, Antoni G, Bjorkman M, Forngren BH, Forngren T, Hartvig P, Markides K, Yngve U, Ogren M (1999) Compounds labelled with short-lived β+-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. Acta Chem Scand 53:651–669
Kihlberg T, Karimi F, Långström B (2002 [11C] Carbon monoxide in selenium-mediated synthesis of 11C-carbamoyl compounds. J Org Chem 67:3687–3692
Karimi F, Kihlberg T et al (2001) [11C/13C]Carbon monoxide in palladium-mediated reactions to prepare 11C-labelled imides. J Chem Soc Perkin Transact I 2001:1528–1531
Karimi F, Långström B (2002) Palladium mediated synthesis of [carboxy-11C]amides and hydrazides using [11C] carbon monoxide. J Chem Soc Perkin I 2002:2111–2115
Karimi F, Långström B (2002) Palladium-mediated carboxylation of aryl halides (triflates) or benzyl halides using (13C)/[11C] carbon monoxide with tetrabutylammonium hydroxide or trimethylphenylammonium hydroxide. J Chem Soc Perkin Trans 1:2256–2259
Karimi F, Långström B (2003) Synthesis of 11C-labelled amides by palladium-mediated carboxamination using [11C] carbon monoxide, in situ activated amines and 1,2,2,6,6-pentamethylpiperidine. Eur J Org Chem 11:2132–2137
Karimi F, Långström B (2003) Synthesis of 11C-amides using [11C] carbon monoxide and in situ activated amines by palladium-mediated carboxaminations. Org Biomol Chem 541–546
Bjurling P, R Reineck et al (1996) Synthia, a compact radiochemistry system for automated production of radiopharmaceuticals. Sixth workshop on targetry and target chemistry, Vancouver, Canada
Forngren BH, Tyrefors N, Markides KE, Langstrom B (2000) Determination of raclopride in human plasma by on-column focusing packed capillary liquid chromatography-electrospray ionisation mass spectrometry. J Chromatogr B Biomed Sci Appl 748:189–195
Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G, Langstrom B (2000) PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer11C-metomidate. J Nucl Med 41:275–282
Hartvig P, Bergstrom K, Lindberg B, Lundberg PO, Lundqvist H, Langstrom B, Svard H, Rane A (1984) Kinetics of11C-labeled opiates in the brain of rhesus monkeys. J Pharmacol Exp Ther 230:250–255
Lundberg T, Lindstrom LH, Hartvig P, Eckernas SA, Ekblom B, Lundqvist H, Fasth KJ, Gullberg P, Langstrom B (1989) Striatal and frontal cortex binding of11C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology 99:8–12
Neu H, Hartvig P, Torstenson R, Fasth KJ, Sonesson C, Waters N, Carlsson A, Tedroff J, Langstrom B (1997) Synthesis of [11C-methyl]-(−)-OSU6162, its regional brain distribution and some pharmacological effects of (−)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. Nucl Med Biol 24:507–511
Feldman HS, Hartvig P, Wiklund L, Doucette AM, Antoni G, Gee A, Ulin J, Langstrom B (1997) Regional distribution of11C-labeled lidocaine, bupivacaine, and ropivacaine in the heart, lungs, and skeletal muscle of pigs studied with positron emission tomography. Biopharm Drug Dispos 18:151–164
Bergstrom M, Cass LM, Valind S, Westerberg G, Lundberg EL, Gray S, Bye A, Langstrom B (1999) Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet 36[Suppl 1]:33–39
Bergstrom M, Fasth KJ, Kilpatrick G, Ward P, Cable KM, Wipperman MD, Sutherland DR, Langstrom B (2000) Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. Neuropharmacology 39:664–670
Hartvig P, Bergström M, Antoni G, Långström B (2002) Positron emission tomography and brain monoamine neurotransmission—entries for study of drug interactions. Curr Pharm Des 8:1417–1434
Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2:233–240
Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL, Twelves C (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 21:203–210
Tilsley DW, Harte RJ, Jones T, Brady F, Luthra SK, Brown G, Price PM (1993) New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. Cancer Surv 17:425–442
Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles SS, Price P (2002) Cancer research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 86:1052–1056
Holford NH (1990) Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling. Fundam Clin Pharmacol 4[Suppl 2]:93s–101s
Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67–95
Acknowledgements
This concept was activated in part in collaboration with GSK promoted by Garth Rapeport and in discussions with the Swedish Medical Product Agency, which is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bergström, M., Grahnén, A. & Långström, B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59, 357–366 (2003). https://doi.org/10.1007/s00228-003-0643-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0643-x